Abstract
Background
Flecainide is a class IC antiarrhythmic drug that is contraindicated in patients who have a history of myocardial infarction, but its effect on mortality and risk of proarrhythmia in patients with stable obstructive and nonobstructive epicardial coronary artery disease (CAD) has not been assessed.
Objective
We sought to compare the safety of flecainide administration in patients who had angiographic evidence of either no or minimal CAD versus nonobstructive CAD, and those who underwent nuclear stress testing with perfusion defects versus those without perfusion defects.
Methods
We conducted a retrospective chart review of 348 patients who were treated with flecainide for at least 1 year duration and underwent evaluation for CAD with coronary angiography or myocardial perfusion imaging (MPI) stress testing within 3 months of initiating flecainide. We compared overall mortality and proarrhythmia between varying levels of CAD and perfusion defects.
Results
There was a similar 10-year survival between those with no or minimal CAD, nonobstructive CAD, and obstructive CAD (p = 0.6). Additionally, there was no difference in arrhythmia burden, including sustained ventricular tachycardias or frequent premature ventricular contractions (> 5% daily burden; p = 0.25). There was also no increase in mortality among those who had reversible perfusion defects >0% compared with those without, among subjects who underwent MPI (p = 0.14). On subgroup analysis, there was no increased risk in all-cause mortality with any specific coronary artery involvement, or with obstructive multivessel CAD (p = 0.89).
Conclusion
Flecainide use is not associated with an increase in either all-cause mortality or ventricular arrhythmias in low-risk patients with stable nonobstructive CAD.
Similar content being viewed by others
References
Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76–85.
Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 1987;59(15):1337–41.
Suttorp MJ, Kingma JH, Jessurun ER, Lie AHL, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16(7):1722–7.
Suttorp MJ, Kingma JH, Lie AHL, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989;63(11):693–6.
Kim SS, Lal R, Ruffy R. Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol. 1986;58(1):80–5.
Ward DE, Jones S, Shinebourne EA. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff–Parkinson–White syndrome. Am J Cardiol. 1986;57(10):787–90.
Ward D, Jones S, Shinebourne E. The use of flecainide acetate for control of junctional tachycardias in children. Circulation. 1984;70(4):207.
Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol. 1988;62(6):35D-D37.
Vangelder IC, Crijns HJGM, Vangilst WH, Vanwijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial-fibrillation or atrial-flutter. Am J Cardiol. 1989;64(19):1317–21.
Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80(6):1557–70.
Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fuca G, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37(2):548–53.
Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm. 2018;15(2):159–63.
Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15(4):380–3.
Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol. 2017;2(7):759–66.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–8.
Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993;270(20):2451–5.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-267.
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272–391.
Barnett AS, Kim S, Fonarow GC, Thomas LE, Reiffel JA, Allen LA, et al. Treatment of atrial fibrillation and concordance with the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: findings from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017;10(11):e005051.
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
Halperin JL, Williams ES, Fuster V, et al. ACC 2015 core cardiovascular training statement (COCATS 4) (revision of COCATS 3). A report of the ACC Competency Management Committee. J Am Coll Cardiol. 2015;65(17):1721–3.
Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation. 1993;87(2):562–72.
Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1994;90(6):2843–52.
Faber TS, Zehender M, Krahnefeld O, Daisenberger K, Meinertz T, Just H. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 1997;29(3):561–7.
Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407.
Acknowledgements
The authors acknowledge the assistance of Skye Buckner-Petty and Katrina Devick, who provided statistical assistance for this project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported by the Mayo Clinic Department of Cardiovascular Diseases, which provided internal funding for this work.
Conflict of interest
Hasan Ashraf, Nway Ko Ko, Vatsal Ladia, Pradyumna Agasthi, Tadhg Prendiville, Fergus O’Herlihy, Sai Harika Pujari, Siva K. Mulpuru, Luis Scott, and Dan Sorajja declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
Rights and permissions
About this article
Cite this article
Ashraf, H., Ko, N.K., Ladia, V. et al. Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease. Am J Cardiovasc Drugs 21, 563–572 (2021). https://doi.org/10.1007/s40256-021-00483-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-021-00483-9